Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010
Djamila E. Issa(Jeroen Bosch Ziekenhuis), O. Visser(Netherlands Comprehensive Cancer Organisation), Henrike E. Karim‐Kos(Erasmus University Rotterdam), Sonja Zweegman(Vrije Universiteit Amsterdam), S.A.M. van de Schans(Netherlands Comprehensive Cancer Organisation), Mariëlle J. Wondergem(Amsterdam UMC Location Vrije Universiteit Amsterdam), Martine E.D. Chamuleau(Hovon), Peter C. Huijgens(Netherlands Comprehensive Cancer Organisation), J.W.W. Coebergh(Erasmus University Rotterdam)
Cited by 57
Related Papers
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
|The Lancet|2021|337
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
|Blood|2019|136